Overview
Adenocarcinoma of the esophagus (EAC) is a highly aggressive malignancy that arises predominantly in the distal esophagus, often associated with Barrett's esophagus (BE), a condition characterized by metaplastic columnar epithelium replacing the normal squamous mucosa. This cancer has seen a significant rise in incidence across developed countries over recent decades, posing a substantial clinical challenge due to its poor prognosis, with a reported overall survival rate of only 13.7% 1. Early detection and intervention are crucial, as EAC is typically lethal without timely diagnosis. Understanding risk factors and implementing effective screening strategies are essential in day-to-day practice to mitigate its impact 137.Pathophysiology
The development of EAC from BE involves a multistep process influenced by both genetic and environmental factors. Initially, chronic gastroesophageal reflux leads to esophageal epithelial damage, promoting metaplasia where squamous cells are replaced by columnar cells, characteristic of BE. Over time, progressive genetic alterations play a pivotal role in disease progression. Key molecular events include mutations in tumor suppressor genes such as TP53 and CDKN2A, which are critical in cell cycle regulation and apoptosis 128. Additionally, DNA content abnormalities like tetraploidy and aneuploidy contribute significantly to the malignant transformation 2830. The cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway also emerges as a crucial mediator, promoting inflammation and carcinogenesis through various downstream effects on cell proliferation and survival 56. These molecular changes collectively drive the transition from BE to invasive EAC 156.Epidemiology
Esophageal adenocarcinoma predominantly affects older adults, with a median age at diagnosis around 60 years, and shows a male predominance 117. Its incidence has risen dramatically in Western countries, including the United States, Western Europe, and Australia, over the past few decades, with no signs of abating 117. Risk factors include obesity, smoking, alcohol consumption, and a history of gastroesophageal reflux disease (GERD) 17. Geographic variations exist, with higher incidence rates noted in industrialized regions, possibly linked to lifestyle factors such as diet and obesity 117. Trends indicate an increasing prevalence, underscoring the need for enhanced screening and preventive strategies 117.Clinical Presentation
Patients with EAC often present with nonspecific symptoms in early stages, including dysphagia, weight loss, and chest pain, which can be mistaken for benign esophageal disorders 1. More advanced cases may exhibit severe dysphagia, leading to malnutrition and cachexia. Red-flag features include unintentional weight loss, persistent dysphagia, and recurrent chest infections, necessitating urgent evaluation 13. Early detection remains challenging due to these subtle presentations, highlighting the importance of targeted screening in high-risk populations 13.Diagnosis
The diagnostic approach for EAC involves a combination of clinical evaluation, endoscopic assessment, and histopathological confirmation. Key steps include:Specific Criteria and Tests:
Differential Diagnosis:
Management
Initial Treatment
Adjuvant Therapy
Palliative Care
Complications
Prognosis & Follow-up
Prognosis for EAC is generally poor, with survival significantly influenced by stage at diagnosis. Early-stage disease offers better outcomes compared to advanced stages. Key prognostic indicators include tumor size, lymph node involvement, and histological grade 120. Recommended follow-up includes:Special Populations
Key Recommendations
References
1 Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD et al.. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS medicine 2007. link 2 Kuwabara S, Kobayashi K, Sudo N, Nobuhiro M, Tashiro A. Pedunculated gastric tube with distal partial gastrectomy for esophageal reconstruction in synchronous or metachronous esophagectomy. Updates in surgery 2025. link 3 Bell MG, Iyer PG. Innovations in Screening Tools for Barrett's Esophagus and Esophageal Adenocarcinoma. Current gastroenterology reports 2021. link 4 Mao Z, Wang B, Dong P, Huang J. The completely mobilized remnant stomach: A new choice to reconstruct the esophagus in lower thoracic esophageal carcinoma with a history of distal gastrectomy. Surgical oncology 2018. link 5 Piazuelo E, Santander S, Cebrián C, Jiménez P, Pastor C, García-González MA et al.. Characterization of the prostaglandin E2 pathway in a rat model of esophageal adenocarcinoma. Current cancer drug targets 2012. link 6 Li S, Tian D, Fei P, Gao Y, Chen Z, Wang Q et al.. A cyclooxygase-2 inhibitor NS-398-enhanced apoptosis of esophageal carcinoma cell EC9706 by adjusting expression of survivin and caspase-3. Cancer investigation 2011. link 7 Gammon MD, Terry MB, Arber N, Chow WH, Risch HA, Vaughan TL et al.. Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2004. link 8 Lamblin A, Mariette C, Triboulet JP. Adenocarcinoma in a gastric tube after esophagectomy for esophageal carcinoma. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus 2003. link